

1 March 2023

ASX Announcement
Section 708A Notification

InhaleRx Ltd (ASX:IRX) (the "Company") refers to the issue of 2,500,000 ordinary shares in the Company on 1 March 2023.

The Corporations Act 2001 (the Act) restricts the on-sale of securities issued without disclosure, unless the sale is exempt under Section 708 or 708A of the Act. By the Company giving this notice, sale of securities noted above will fall within the exemption in Section 708A (5) of the Act.

In accordance with section 708A (6) of the Act, the following information is provided:

- a) this notice is given within 5 business days after the day of the issue;
- b) the issue is without disclosure to investors under Part 6D.2 of the Act;
- c) this notice is given under section 708A(5)(e) of the Act;
- d) as at the date of this notice, the Company has complied with the provisions of Chapter 2M of the Act as they apply to the Company and section 674 of the Act; and
- e) as at the date of this notice, there is no excluded information to be provided in accordance with section 708A(7) and (8) of the Act.

Authorised by the Board of Directors.

For further information:
www.inhalerx.com.au

Nova Taylor
Phone +61 3 8678 4091

About InhaleRx Limited (ASX: IRX) – www.inhalerx.com.au

InhaleRx Limited is an Australian healthcare and technology company which is focused on developing inhalation therapies. The Company currently markets the Medihale inhalation device and is working on developing a range of inhaled therapeutic medicinal formulations for registration domestically and internationally.